Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096039 | 0.91 | SCN9A (0.40) | SCN9AKMT2AMEN1NPC1GAA | |
| SCHEMBL6096935 | 0.91 | P2RY12 (0.43) | KMT2AGAASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6095053 | 0.86 | SCN9A (0.53) | SCN9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL6097694 | 0.84 | SCN9A (0.45) | SCN9AKMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL6096053 | 0.83 | HSD11B1 (0.42) | SCN9AKMT2AMEN1GAAHSD11B1 | |
| SCHEMBL6097174 | 0.82 | NPSR1 (0.39) | KMT2AGAASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6096049 | 0.81 | SCN9A (0.42) | SCN9ANPC1 | |
| SCHEMBL6098034 | 0.81 | KMT2A (0.39) | SCN9AKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL6095940 | 0.79 | NPC1 (0.41) | KMT2AMEN1NPC1GAAL3MBTL1 | |
| SCHEMBL27578058 | 0.78 | SCN9A (0.58) | SCN9AKMT2AMEN1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | claimed |
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | SCN9A 2601/4885KMT2A 2280/4885MEN1 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.